Corbus Pharmaceuticals Holdings (CRBP) Gains from Investment Securities (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly Gains from Investment Securities of $1.4 million in Q4 2025, down 3.52% quarter-over-quarter from $1.4 million in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Gains from Investment Securities (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Gains from Investment Securities history runs 13 years deep, the most recent figure standing at $1.4 million for Q4 2025.
- In Q4 2025, Gains from Investment Securities changed N/A year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.4 million (up 1367.96% YoY), while the FY2025 annual figure was $1.4 million, up 91.66% from the prior year.
- Gains from Investment Securities was $1.4 million for Q4 2025 at Corbus Pharmaceuticals Holdings, down from $1.4 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $6.1 million in Q3 2021 to a low of -$213000.0 in Q1 2024.
- Historically, Gains from Investment Securities has averaged $968329.7 across 5 years, with a median of $290960.5 in 2022.
- Biggest YoY gain for Gains from Investment Securities was 2776.1% in 2024; the steepest drop was 329.8% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$90421.0 in 2021, then jumped by 273.3% to $156704.0 in 2022, then slumped by 92.98% to $11000.0 in 2023, then jumped by 398.9% to $54879.0 in 2024, then surged by 2425.59% to $1.4 million in 2025.
- The last three Gains from Investment Securities figures came in at $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $714375.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Corbus Pharmaceuticals Holdings | 135.08 Mn | 107.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.39 Mn |
| Dec 31, 2025 | 1.39 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Jun 30, 2025 | 714,375.00 |
| Jun 30, 2025 | 714,375.00 |
| Mar 31, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Sep 30, 2024 | 54,879.00 |
| Sep 30, 2024 | 54,879.00 |
| Jun 30, 2024 | 737,979.00 |
| Jun 30, 2024 | 737,979.00 |
| Mar 31, 2024 | -213,000.00 |
| Mar 31, 2024 | -213,000.00 |
| Dec 31, 2023 | 11,000.00 |
| Dec 31, 2023 | 11,000.00 |
| Sep 30, 2023 | 28,576.00 |
| Sep 30, 2023 | 28,576.00 |
| Jun 30, 2023 | 25,659.00 |
| Jun 30, 2023 | 25,659.00 |